基础医学与临床 ›› 2017, Vol. 37 ›› Issue (2): 273-276.
• 医学教育 • 上一篇 下一篇
王煜1,卢建华2,赵太宏3,肖雨龙3
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
摘要: 通过对部分国家和地区罕见病法案的分析,探讨罕见病管理的国际经验。中国应尽快推进罕见病立法,明确罕见病界定标准,加强转化医学研究,提高罕见病诊断治疗水平。应加强政策导向作用,完善激励措施,加强多部门协作,建立健全罕见病医疗保障体系,建立与中国国情相适应的罕见病管理体系。
关键词: 罕见病, 罕用药, 立法, 界定标准
Abstract: Through analyses of rare diseases management of several country and regions, successful practices have been discussed. Legislation of rare diseases should be activated as soon as possible to produce specific standard of rare diseases. Accelerating development of translational medicine could be a feasible approach to improve the level of diagnosis and treatment of rare diseases. Strengthening the orientation of management policies should be put into a more significant position to promote incentives of stakeholder in this area. Both enhancing the joint collaboration of different departments and perfecting medical insurance system could be forceful accelerants to create and optimize the management system of rare diseases in China.
Key words: rare diseases, orphan drug, legislation, definition standards
中图分类号:
R95
王煜 卢建华 赵太宏 肖雨龙. 国外罕见病管理制度对中国的启示[J]. 基础医学与临床, 2017, 37(2): 273-276.
/ 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2017/V37/I2/273